DaVita Venture Group (DVG) is the corporate venture capital arm of DaVita, a leading kidney care provider. It invests in, develops, and incubates companies and products that improve care for patients with kidney disease and related conditions, with a focus on digital health, pharmaceuticals, medical devices, and care delivery models.
33% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $71.9M (across 8 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 R1 Therapeutics | Series A | $77.5M | Mar 2026 |
| EElara Caring | Unknown | — | Feb 2026 |
| PPathalys Pharma | Series B | $105M | Aug 2024 |
 Pathalys | Growth | $150M | Jan 2023 |
| CConsejoSano | Series B | $17M | Dec 2020 |
 Wellth | Series A | $10M | May 2020 |
 Heartbeat | Series B | $20M | — |
 Dock Health | Seed | $5M | — |
 eGenesis | Series D | $191M | — |
Top Co-Investors
Abingworth LLP2 shared
Catalys Pacific2 shared
Impact Engine1 shared
Salesforce Ventures1 shared
7wire Ventures1 shared
Magnetic1 shared
Rock Health1 shared
AVP1 shared
Worklife1 shared
I2BF Global Ventures1 shared
Yabeo1 shared
NF Ventures1 shared
OrbiMed1 shared
The Carlyle Group1 shared
F-Prime Capital1 shared
SymBiosis1 shared
Designer Fund1 shared
Techstars1 shared
Last updated: 9 September 2026